




RealRate

PHARMACEUTICAL 2017

GYRE Therapeutics INC
Rank 204 of 308

CATALYST
BIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 48% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	37,521
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,965
Liabilities, Non-Current	0
Other Assets	125
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	54
Other Net Income	3,872
Other Revenues	0
Property and Equipment	444
Research and Development	11,555
Selling, General and Administrative Expense	9,262

Output Variable	Value in 1000 USD
Assets	38,090
Liabilities	22,019
Expenses	20,817
Revenues	0
Stockholders Equity	16,071
Net Income	-16,945
Comprehensive Net Income	-16,946
BaseVar	42,400
ECR before LimitedLiability	60%
Economic Capital Ratio	197%